<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="A study comparing the efficacy of hydrogen peroxide disinfection versus" exact="alcohol" post="swabs determined that there was a more significant reduction"/>
 <result pre="use of antiviral drugs such as ganciclovir, ribavirin, and cidofovir.41–44" exact="Ganciclovir" post="(GCV), a synthetic nucleoside analog of 2ʹ-deoxyguanosine, has been"/>
 <result pre="ophthalmic gel, interferon eye drops, a tobramycin-dexamethasone combo, and topical" exact="diclofenac" post="sodium. In this study, interferon was administered with the"/>
 <result pre="side effects, such as inflammation, congestion, and edema, tobramycin-dexamethasone and" exact="diclofenac" post="sodium treatments were also employed. This combination of drugs"/>
 <result pre="of the disease, and lessen the risk of corneal complications.27" exact="Valganciclovir" post="is a pro-drug of GCV that inhibits replication of"/>
 <result pre="likely become a challenge in the treatment of adenoviral keratoconjunctivitis.47" exact="Ribavirin" post="and cidofovir have also been shown to exhibit antiviral"/>
 <result pre="a challenge in the treatment of adenoviral keratoconjunctivitis.47 Ribavirin and" exact="cidofovir" post="have also been shown to exhibit antiviral activity against"/>
 <result pre="antiviral therapies lead to the risk of significant side effects." exact="Cidofovir" post="(CDV) is an acyclic nucleoside phosphonate and nucleotide analog"/>
 <result pre="polymerase, causing viral DNA chain termination and viral inhibition.13,44 Intravenous" exact="cidofovir" post="is often used in transplant clinics with only mild"/>
 <result pre="ocular toxicity around the skin of eyelids and conjunctiva.46 Similarly," exact="ribavirin" post="also results in poor systemic side effects and safety"/>
 <result pre="infiltrates. This study showed great promise in the future of" exact="cidofovir" post="for the treatment of ocular HAdV infections in the"/>
 <result pre="therapeutic use. Gordon et al described the effects of topical" exact="cidofovir" post="in uninfected animals, determining that there was consistent clinically"/>
 <result pre="Even at lower and presumably ineffective dosages, 3.5 mg of" exact="cidofovir" post="continued exhibit significant ocular surface toxicity in vivo.52 Resistance"/>
 <result pre="to be an ophthalmic form.13,44 When antiviral comparison is made," exact="ganciclovir" post="appears to be the most favorable in terms of"/>
 <result pre="Nwanegbo et al found that Ig was actually comparable to" exact="cidofovir" post="in its antiviral activity. While cidofovir acts intracellularly to"/>
 <result pre="was actually comparable to cidofovir in its antiviral activity. While" exact="cidofovir" post="acts intracellularly to block DNA replication, Ig neutralizes the"/>
 <result pre="neutralizes the virus on the ocular surface. In comparison to" exact="cidofovir" post="and saline titers, Ig was more effective during the"/>
 <result pre="be beneficial in prophylaxis to prevent clinical infections. Though both" exact="cidofovir" post="and Ig were effective in this study, cidofovir demonstrated"/>
 <result pre="Though both cidofovir and Ig were effective in this study," exact="cidofovir" post="demonstrated a significantly shorter duration of viral shedding. This"/>
 <result pre="the first to investigate NSAID effects on adenoviral replication, specifically" exact="ketorolac" post="tromethamine and diclofenac sodium ophthalmic solutions. During both the"/>
 <result pre="first to investigate NSAID effects on adenoviral replication, specifically ketorolac" exact="tromethamine" post="and diclofenac sodium ophthalmic solutions. During both the early"/>
 <result pre="investigate NSAID effects on adenoviral replication, specifically ketorolac tromethamine and" exact="diclofenac" post="sodium ophthalmic solutions. During both the early and late"/>
 <result pre="did it affect the duration of viral shedding. In contrast," exact="prednisolone" post="treatment was shown to prolong viral shedding.73 As it"/>
 <result pre="viral shedding.73 As it pertained to sub-epithelial infiltrates, treatment with" exact="diclofenac" post="or ketorolac did not yield a statistically significant reduction"/>
 <result pre="As it pertained to sub-epithelial infiltrates, treatment with diclofenac or" exact="ketorolac" post="did not yield a statistically significant reduction when compared"/>
 <result pre="a statistically significant reduction when compared to control groups, whereas" exact="prednisolone" post="did. This study suggests that NSAIDs are not likely"/>
 <result pre="of using corticosteroids or to limit associated corticosteroid complications. Topical" exact="cyclosporine" post="(both 1% and 2% concentrations) is an alternative option"/>
 <result pre="3–4 weeks.64,66,69,78 Okumus et al studied the efficacy of 0.05%" exact="cyclosporine" post="(Restasis®, Allergan, Irvine, California, USA) once per day or"/>
 <result pre="due to subsequent, elevated IOP. After one month of 0.05%" exact="cyclosporine" post="treatment, 81.75% of eyes had cleared SEIs while the"/>
 <result pre="treatment options for acute adenoviral keratoconjunctivitis using either topical 1%" exact="prednisolone" post="acetate in conjunction with non-preserved artificial tears, topical 2%"/>
 <result pre="In comparison to artificial tears alone, both the corticosteroid and" exact="cyclosporine" post="groups exhibited improvement in symptoms as well as a"/>
 <result pre="well as a shorter duration. Both the Cyclosporine A and" exact="prednisolone" post="groups were also similarly effective in preventing the development"/>
 <result pre="during the active phase of infection, suggesting possible prophylactic benefit.72" exact="Tacrolimus" post="is another immunosuppressive agent that also demonstrates anti-inflammatory activity."/>
 <result pre="to prevent rejection in organ transplants. However, despite similar effects," exact="tacrolimus" post="and cyclosporine differ in their chemical makeup. Cyclosporine is"/>
 <result pre="rejection in organ transplants. However, despite similar effects, tacrolimus and" exact="cyclosporine" post="differ in their chemical makeup. Cyclosporine is a cyclic"/>
 <result pre="calcineurin inhibitors, an enzyme necessary for T cell replication.82,83 When" exact="cyclosporine" post="and tacrolimus enter T cells, they bind to their"/>
 <result pre="an enzyme necessary for T cell replication.82,83 When cyclosporine and" exact="tacrolimus" post="enter T cells, they bind to their respective immunophilins,"/>
 <result pre="survival of CD4+ T cells and CD8+ T cells.70,84-86 Topical" exact="tacrolimus" post="0.03% has ophthalmic uses, mainly in the treatment of"/>
 <result pre="vernal keratoconjunctivitis. With regards to its effect on HAdV keratoconjunctivitis," exact="tacrolimus" post="was more effective than dexamethasone in the reduction of"/>
 <result pre="its effect on HAdV keratoconjunctivitis, tacrolimus was more effective than" exact="dexamethasone" post="in the reduction of SEIs, and subsequently in the"/>
 <result pre="of vision and symptomology. This study is significant in that" exact="tacrolimus" post="was not only superior to topical corticosteroids in the"/>
 <result pre="Generally, for SEIs that are resistant to tapering of corticosteroid," exact="tacrolimus" post="0.03% was proven to be an effective corticosteroid-sparing agent.87"/>
 <result pre="antiviral use appears to be synergistic and efficacious.44 Cardiotonic steroids" exact="digoxin" post="and digitoxin have been suggested to offer a new"/>
 <result pre="appears to be synergistic and efficacious.44 Cardiotonic steroids digoxin and" exact="digitoxin" post="have been suggested to offer a new strategy to"/>
 <result pre="ATPase is an important cell signaling molecule, where binding with" exact="digoxin" post="or digitoxin initiates multiple signaling cascades, influencing gene expression."/>
 <result pre="an important cell signaling molecule, where binding with digoxin or" exact="digitoxin" post="initiates multiple signaling cascades, influencing gene expression. These drugs"/>
 <result pre="viral shedding.52 When comparing PVI/dexamethasone combination treatment with that of" exact="dexamethasone" post="alone, combination drops not only increase recovery but also,"/>
 <result pre="virtue of affecting the subepithelial layer. Transepithelial PTK low dose" exact="mitomycin" post="C has shown benefit in such cases with reported"/>
 <result pre="Dry eye symptoms, corneal epithelial damage/toxicity with repeated use. 104" exact="Cidofovir" post="Antiviral activity against HAdV5 exhibited in animal models. 105Cidofovir"/>
 <result pre="associated with rare cases of lacrimal canalicularblockade in rabbit models.107" exact="Ganciclovir" post="3% ganciclovir reduced HAdV 5 replication and pathogenesis in"/>
 <result pre="rare cases of lacrimal canalicularblockade in rabbit models.107 Ganciclovir 3%" exact="ganciclovir" post="reduced HAdV 5 replication and pathogenesis in animal models.108"/>
 <result pre="ganciclovir reduced HAdV 5 replication and pathogenesis in animal models.108" exact="Ganciclovir" post="is efficacious against HAdV types that cause EKC.46 Ganciclovir"/>
 <result pre="models.108 Ganciclovir is efficacious against HAdV types that cause EKC.46" exact="Ganciclovir" post="ophthalmic gel treatment prevents complications in adenoviral ocular infection."/>
 <result pre="EKC symptoms and Persistent adenoviral SEIs.2,63 Glaucoma and cataracts.116 Topical" exact="cyclosporine" post="Effective against persistent adenoviral SEIs.66,69,117–119 Transient or long-lasting burning"/>
 <result pre="ocular pain/irritation, redness; eyelid swelling in Steven Johnsons patients.121 Topical" exact="tacrolimus" post="Superior to dexamethasone in reducing symptomology and SEIs70 as"/>
 <result pre="eyelid swelling in Steven Johnsons patients.121 Topical tacrolimus Superior to" exact="dexamethasone" post="in reducing symptomology and SEIs70 as well as a"/>
 <result pre="ganciclovir, cidofovir, PVI irrigation Poor bioavailability and high toxicity of" exact="cidofovir" post="Lipid-linked derivative brincidofovir and potential development of ophthalmic formulation"/>
 <result pre="(ie, elevated IOP and cataract formation) Immunotherapy such as topical" exact="cyclosporine" post="or tacrolimus Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic"/>
 <result pre="IOP and cataract formation) Immunotherapy such as topical cyclosporine or" exact="tacrolimus" post="Corticosteroids prolonging viral shedding Combination PVI/dexamethasone ophthalmic solution Conjunctival"/>
 <result pre="42.KimSJ, KimK, ParkSB, HongDJ, JhunBW. Outcomes of early administration of" exact="cidofovir" post="in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One."/>
 <result pre="pneumonia. PLoS One. 2015;10(4):e0122642. doi:10.1371/journal.pone.012264225875735 43.YingB, TollefsonAE, SpencerJF, et al." exact="Ganciclovir" post="inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed"/>
 <result pre="BoeckhM. Adenovirus infection in hematopoietic stem cell transplantation: effect of" exact="ganciclovir" post="and impact on survival. Biol Blood Marrow Transplant. 2003;9(5):341–352."/>
 <result pre="Marrow Transplant. 2003;9(5):341–352. doi:10.1016/S1083-8791(03)00102-212766884 46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects of" exact="ganciclovir" post="in types inducing keratoconjunctivitis by quantitative polymerase chain reaction"/>
 <result pre="methods. Clin Ophthalmol. 2014;8:315–320. doi:10.2147/OPTH.S5528424511226 47.TothK, YingB, TollefsonAE, et al." exact="Valganciclovir" post="inhibits human adenovirus replication and pathology in permissive immunosuppressed"/>
 <result pre="2015;7(3):1409–1428. doi:10.3390/v703140925807051 48.de OliveiraCB, StevensonD, LaBreeL, McDonnellPJ, TrousdaleMD. Evaluation of" exact="Cidofovir" post="(HPMPC, GS-504) against adenovirus type 5 infection in vitro"/>
 <result pre="doi:10.1016/0166-3542(95)00962-08811201 49.RomanowskiEG, YatesKA, GordonYJ. Antiviral prophylaxis with twice daily topical" exact="cidofovir" post="protects against challenge in the adenovirus type 5/New Zealand"/>
 <result pre="al. Clinical and antiviral efficacy of an ophthalmic formulation of" exact="dexamethasone" post="povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest"/>
 <result pre="2000;19(1):69–85. doi:10.1016/S1350-9462(99)00004-X10614681 64.HillenkampJ, ReinhardT, RossRS, et al. The effects of" exact="cidofovir" post="1% with and without cyclosporin a 1% as a"/>
 <result pre="et al. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2%" exact="cidofovir" post="and 1% cyclosporine: a controlled clinical pilot study. Arch"/>
 <result pre="doi:10.1001/archopht.119.10.148711594949 66.LevingerE, SlomovicA, SansanayudhW, BaharI, SlomovicAR. Topical treatment with 1%" exact="cyclosporine" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638–640."/>
 <result pre="adenoviral keratoconjunctivitis. Cornea. 2010;29(6):638–640. doi:10.1097/ICO.0b013e3181c3303420458220 67.ReinhardT, GodehardtE, PfahlHG, SundmacherR. [Local" exact="cyclosporin A" post="in nummuli after keratoconjunctivitis epidemica. A pilot study]. Ophthalmologe."/>
 <result pre="pilot study]. Ophthalmologe. 2000;97(11):764–768. German. doi:10.1007/s003470070025.11130165 68.KilicA, GurlerB. Topical 2%" exact="cyclosporine" post="A in preservative-free artificial tears for the treatment of"/>
 <result pre="70.BhargavaR, KumarP. Comparison of the safety and efficacy of topical" exact="Tacrolimus" post="(0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral"/>
 <result pre="of the safety and efficacy of topical Tacrolimus (0.03%) versus" exact="dexamethasone" post="(0.05%) for subepithelial infiltrates after adenoviral conjunctivitis. Indian J"/>
 <result pre="uses. Surv Ophthalmol. 1986;31(3):159–169. doi:10.1016/0039-6257(86)90035-43544293 78.RomanowskiEG, PlessP, YatesKA, GordonYJ. Topical" exact="cyclosporine" post="A inhibits subepithelial immune infiltrates but also promotes viral"/>
 <result pre="experimental adenovirus models. Cornea. 2005;24(1):86–91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT, YeeRW, WildJH. Topical" exact="cyclosporine" post="therapy for ulcerative keratitis associated with rheumatoid arthritis. Am"/>
 <result pre="J Ophthalmol. 1990;109(5):610–612. doi:10.1016/S0002-9394(14)70704-42333932 80.HollandEJ, OlsenTW, KetchamJM, et al. Topical" exact="cyclosporin A" post="in the treatment of anterior segment inflammatory disease. Cornea."/>
 <result pre="inflammatory disease. Cornea. 1993;12(5):413–419. doi:10.1097/00003226-199309000-000088306663 81.PerryHD, Doshi-carnevaleS, DonnenfeldED, KornsteinHS. Topical" exact="cyclosporine" post="A 0.5% as a possible new treatment for superior"/>
 <result pre="Pharmacokinet. 1993;24(6):472–495. doi:10.2165/00003088-199324060-000048513650 83.ThomsonAW, BonhamCA, ZeeviA. Mode of action of" exact="tacrolimus" post="(FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–591."/>
 <result pre="Monit. 1995;17(6):584–591. doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary:" exact="cyclosporine" post="and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ."/>
 <result pre="doi:10.1097/00007691-199512000-000078588225 84.BarbarinoJM, StaatzCE, VenkataramananR, KleinTE, AltmanRB. PharmGKB summary: cyclosporine and" exact="tacrolimus" post="pathways. Pharmacogenet Genomics. 2013;23(10):563–585. doi:10.1097/FPC.0b013e328364db8423922006 85.BoymanO, SprentJ. The role"/>
 <result pre="Immunol. 2012;12(3):180–190. doi:10.1038/nri315622343569 86.AlmawiWY, MelemedjianOK. Clinical and mechanistic differences between" exact="FK506" post="(tacrolimus) and cyclosporin A. Nephrol Dial Transplant. 2000;15(12):1916–1918. doi:10.1093/ndt/15.12.191611096132"/>
 <result pre="86.AlmawiWY, MelemedjianOK. Clinical and mechanistic differences between FK506 (tacrolimus) and" exact="cyclosporin A." post="Nephrol Dial Transplant. 2000;15(12):1916–1918. doi:10.1093/ndt/15.12.191611096132 87.GhanemRC, VargasJF, GhanemVC. Tacrolimus"/>
 <result pre="cyclosporin A. Nephrol Dial Transplant. 2000;15(12):1916–1918. doi:10.1093/ndt/15.12.191611096132 87.GhanemRC, VargasJF, GhanemVC." exact="Tacrolimus" post="for the treatment of subepithelial infiltrates resistant to topical"/>
 <result pre="of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and" exact="dexamethasone" post="0.1% drops: a clinical prospective controlled randomized study. Acta"/>
 <result pre="Ocul Toxicol. 2017;36(4):343–346. doi:10.1080/15569527.2017.129166528166657 105.TollefsonAE, SpencerJF, YingB, BullerRM, WoldWS, TothK." exact="Cidofovir" post="and brincidofovir reduce the pathology caused by systemic infection"/>
 <result pre="with human type 5 adenovirus in immunosuppressed Syrian hamsters, while" exact="ribavirin" post="is largely ineffective in this model. Antiviral Res. 2014;112:38–46."/>
 <result pre="adenovirus keratoconjunctivitis]. Arq Bras Oftalmol. 2011;74(6):417–421. Portuguese. doi:10.1590/S0004-27492011000600007.22331114 109.OzenS, OzerMA." exact="Ganciclovir" post="ophthalmic gel treatment shortens the recovery time and prevents"/>
 <result pre="Cornea. 2011;30(9):958–961. doi:10.1097/ICO.0b013e31820cd60721673568 118.MuftuogluIK, AkovaYA, GungorSG. Effect of 0.05% topical" exact="cyclosporine" post="for the treatment of symptomatic subepithelial infiltrates due to"/>
 <result pre="119.BayraktutarBN, UcakhanOO. Comparison of efficacy of two different topical 0.05%" exact="cyclosporine" post="a formulations in the treatment of adenoviral keratoconjunctivitis-related subepithelial"/>
 <result pre="CaputoR, MoriF, et al. Long-term safety and efficacy of topical" exact="cyclosporine" post="in 156 children with vernal keratoconjunctivitis. Int J Immunopathol"/>
 <result pre="J Immunopathol Pharmacol. 2010;23(3):865–871. doi:10.1177/03946320100230032220943058 121.SchultzC. Safety and efficacy of" exact="cyclosporine" post="in the treatment of chronic dry eye. Ophthalmol Eye"/>
 <result pre="Eye Dis. 2014;6:37–42. doi:10.4137/OED.S1606725002818 122.LevingerE, TrivizkiO, ShacharY, LevingerS, TopicalVD. 0.03%" exact="tacrolimus" post="for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Graefes Arch"/>
 <result pre="Riestra AyoraAC, Lisa FernandezC, Chacon RodriguezM, Merayo-llovesJ, Alfonso SanchezJF. Topical" exact="tacrolimus" post="for corneal subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea."/>
 <result pre="124.BarotRK, ShitoleSC, BhagatN, PatilD, SawantP, PatilK. Therapeutic effect of 0.1%" exact="tacrolimus" post="eye ointment in allergic ocular diseases. J Clin Diagn"/>
</results>
